i-SENS, Inc.

KOSDAQ 099190.KQ

i-SENS, Inc. Capital Expenditure for the year ending December 31, 2023: USD -32.75 M

i-SENS, Inc. Capital Expenditure is USD -32.75 M for the year ending December 31, 2023, a -59.49% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

i-SENS, Inc. Capital Expenditure for the year ending December 31, 2022 was USD -20.54 M, a 49.09% change year over year.
i-SENS, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -40.34 M, a -449.01% change year over year.
i-SENS, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -7.35 M, a -11.86% change year over year.
i-SENS, Inc. Capital Expenditure for the year ending December 31, 2019 was USD -6.57 M, a 30.27% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KOSDAQ: 099190.KQ

i-SENS, Inc.

CEO	Dr. Geun-Sig Cha
IPO Date	Jan. 30, 2013
Location	South Korea
Headquarters	43, Banpo-daero 28-gil
Employees	687
Sector	Consumers Staples
Industries Personal Care Biotechnology Frozen Foods Hardware & Electronics Medical Instruments Non-Alcoholic Beverages Pharmaceuticals Telehealth

Description

i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years